BCRX250516C5000
- 2.30
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BioCryst Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
BioCryst Pharma Analyst Ratings
Cantor Fitzgerald Initiates BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $20
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15
Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target
BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $12
Evercore ISI Sticks to Their Buy Rating for BioCryst (BCRX)
Jefferies Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $12
BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
BioCryst Pharma Analyst Ratings
RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18